COPD and Asthma Inhaler Reference Chart
For COPD and asthma management, use the following structured approach to inhaler selection based on disease severity and phenotype, prioritizing ICS-containing regimens for both conditions while avoiding SABA monotherapy in asthma.
ASTHMA INHALERS
Maintenance Therapy (Track 1 - Preferred)
- Low-dose ICS-formoterol (combination inhaler)
Maintenance Therapy (Track 2 - Alternative)
- Regular low-dose ICS (separate inhaler)
Step-Up Options for Uncontrolled Asthma
- ICS/LABA as maintenance and reliever therapy (SMART)
- Highest rank for preventing exacerbations 2
- Higher-dose ICS for symptom control 2
- Low-dose ICS/LABA for optimal lung function (FEV1) 2
Rescue/Reliever
- SABA alone is NOT recommended as monotherapy 1
- Use ICS-formoterol as needed (Track 1) OR SABA with separate ICS (Track 2)
COPD INHALERS
Initial Maintenance Therapy (Symptomatic Patients)
- Long-acting bronchodilator monotherapy:
- Tiotropium (LAMA, once daily) OR
- Salmeterol/Formoterol (LABA, twice daily)
- Superior to short-acting agents for lung function, dyspnea, exacerbations 3
Step-Up for Persistent Symptoms
High Exacerbation Risk (≥2 exacerbations/year)
- LAMA/LABA/ICS triple therapy (single inhaler preferred)
Blood Eosinophil Guidance for ICS Use
- ≥300 cells/μL: Strong indication for ICS-containing therapy 4
- <300 cells/μL: Consider avoiding ICS or stepping down carefully 4
Refractory Exacerbators (Despite Triple Therapy)
Add-on therapies in order of recommendation:
- Macrolide maintenance (if normal QT, no drug interactions, no mycobacterial infection) 4
- Roflumilast OR N-acetylcysteine (for chronic bronchitic phenotype) 4
Rescue/Reliever
- Short-acting beta-agonist (SABA) with or without short-acting anticholinergic
- MDI with spacer equivalent to nebulizer 5
ACUTE EXACERBATIONS
COPD Exacerbation Treatment
- Bronchodilators: SABA ± short-acting anticholinergic 5
- Systemic corticosteroids: Prednisone 40 mg daily × 5 days 5
- Antibiotics: 5-7 days if indicated (purulent sputum) 5
Asthma Exacerbation
- SABA for immediate relief
- Systemic corticosteroids as needed
- Consider eosinophil levels for steroid responsiveness 5
CRITICAL PITFALLS TO AVOID
- Never use SABA monotherapy in asthma - all patients need ICS-containing therapy 1
- Never use ICS monotherapy in COPD - always combine with long-acting bronchodilators 4
- Do not step down from triple therapy in high-risk COPD exacerbators - especially with eosinophils ≥300 4
- Avoid theophylline and oral corticosteroid maintenance in COPD 4
- High-dose ICS not necessary in COPD - flat dose-response curve, use moderate dose 4
- Verify inhaler technique before escalating therapy - poor technique mimics treatment failure 6
DEVICE SELECTION CONSIDERATIONS
Assess three key patient factors before prescribing:
- Cognitive function - can they understand instructions?
- Manual dexterity - can they coordinate actuation?
- Inhalation ability - adequate inspiratory flow? 6
At follow-up, ask: "Does your current treatment help your breathing?"
- If YES: Continue therapy, review technique
- If NO: Assess technique and adherence before changing medication 6